SpaceX IPO launches today. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElementis Regulatory News (ELM)

Share Price Information for Elementis (ELM)

Share Price is delayed by 15 minutes
Get Live Data
155.40    2.60 (1.70%)
Bid:
155.20
Ask:
155.60
Spread: 0.40 (0.258%)
Market Cap: £889.38m
ELM Live PriceLast checked at - London Stock Exchange

Intraday Elementis Share Chart

Trading Statement

27 Oct 2017 07:00

ELEMENTIS PLC - Trading Statement

ELEMENTIS PLC - Trading Statement

PR Newswire

London, October 26

Elementis plc

Q3 Trading Update

Sustained good revenue performance and overall trading on track

Elementis plc (“Elementis” or the “Group”), a Global Specialty Chemicals Company, today issues its planned period end trading update for the three months ended 30 September 2017.

In the third quarter the Group has performed in line with expectations and seen a continuation of the trends experienced across the first half of the year.

Specialty Products performed well and in line with expectations

Coatings saw a good sales performance across all regions versus last year, however higher raw material costs impacted profit growth.

Personal Care continued to benefit from increased penetration of our hectorite based products across categories and geographies. The integration of SummitReheis remains on track with synergies well underpinned, and we continue to implement pricing responses to recover raw material cost inflation. We are creating a Personal Care business of scale.

Energy has remained strong, reflecting higher activity levels and market share gains. Momentum in the business remains extremely positive.

Chromium on track to deliver full year improvement

Chromium has continued to perform well and in line with the trends experienced across the first half of the year. Despite unplanned production outages at our Castle Hayne and Corpus Christi facilities during the third quarter we continue to expect an improved full year outcome versus 2016.

Surfactants disposal progressing well

As previously indicated, the favourable first half conditions in Surfactants have not continued. The sale process for the business is progressing well and we continue to expect resolution in early 2018.

Commenting on the performance, CEO, Paul Waterman said,

“Elementis has delivered another good revenue performance in the third quarter and overall trading is on track. Trends remain similar to those reported in the first half of the year and we remain on course to grow operating profit across all three segments in 2017. Going forward, we continue to see significant potential for Elementis as we implement our Reignite Growth strategy”.

Enquiries

Elementis plc

James Curran, Investor Relations Tel: 020 7067 2994

Martin Robinson, Tulchan Tel: 020 7353 4200

Date   Source Headline
16th Jan 20251:45 pmRNSHolding(s) in Company
2nd Jan 202510:06 amRNSTotal Voting Rights
24th Dec 20247:00 amRNSDirectorate Change
9th Dec 20245:05 pmRNSDirector/PDMR Shareholding
2nd Dec 202410:06 amRNSTotal Voting Rights
18th Nov 20247:00 amRNSChief Executive Succession
1st Nov 20249:54 amRNSTotal Voting Rights
29th Oct 20247:00 amRNSThird Quarter Trading Update
11th Oct 202411:18 amRNSDirector/PDMR Shareholding
17th Sep 20248:50 amRNSDirector/PDMR Shareholding
2nd Sep 20249:31 amRNSBlock listing Interim Review
23rd Aug 202410:31 amRNSHolding(s) in Company
14th Aug 202410:53 amRNSAdditional Listing
9th Aug 20242:43 pmRNSHolding(s) in Company
2nd Aug 20245:44 pmRNSHolding(s) in Company
1st Aug 20243:10 pmRNSCorrection of dividend record date
1st Aug 20247:00 amRNSHalf-year Report
15th Jul 202410:59 amRNSHolding(s) in Company
30th May 202412:52 pmRNSDirector/PDMR Shareholding
29th May 20241:07 pmRNSDirector Declaration
8th May 202411:08 amRNSDirector/PDMR Shareholding
3rd May 202411:46 amRNSHolding(s) in Company
1st May 202410:06 amRNSTotal Voting Rights
30th Apr 202411:36 amRNSResult of AGM
30th Apr 20247:00 amRNSFirst quarter trading update
29th Apr 202412:13 pmRNSResponse to open letter from Gatemore
12th Apr 202411:33 amRNSDirector/PDMR Shareholding
12th Apr 202411:28 amRNSDirector/PDMR Shareholding
9th Apr 20246:04 pmRNSDirector/PDMR Shareholding
26th Mar 20244:07 pmRNSAnnual Financial Report & Notice of AGM
19th Mar 20243:02 pmRNSAdditional Listing
15th Mar 20241:00 pmRNSDirectorate Change
12th Mar 20244:38 pmRNSDirector/PDMR Shareholding
12th Mar 20244:33 pmRNSDirector/PDMR Shareholding
8th Mar 20245:56 pmRNSDirector/PDMR Shareholding
7th Mar 20247:00 amRNSDirectorate changes
7th Mar 20247:00 amRNSPreliminary results year ended 31 December 2023
1st Mar 20249:30 amRNSBlock listing Interim Review
18th Jan 20247:00 amRNSTrading Update
2nd Jan 20249:45 amRNSTotal Voting Rights
1st Dec 202310:46 amRNSTotal Voting Rights
30th Nov 20239:38 amRNSDirector/PDMR Shareholding
14th Nov 20237:00 amRNS2023 Capital Markets Day
1st Nov 20239:46 amRNSTotal Voting Rights
31st Oct 20237:00 amRNSThird Quarter Trading Update
2nd Oct 20239:34 amRNSTotal Voting Rights
20th Sep 202312:09 pmRNSResponse to open letter from Franklin Templeton
12th Sep 20233:13 pmRNSDirector Declaration
8th Sep 20239:30 amRNSHolding(s) in Company
1st Sep 20239:49 amRNSBlock listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.